FDA News Recap: 5 Approvals to Know from the First Half of 2025

The first half of 2025 has unfolded during a period of uncertainty in public health. From ongoing pressure on healthcare systems to workforce shortages and shifting regulatory dynamics, challenges remain on nearly every front. Yet even amid these headwinds, the pace of medical innovation continues—and in some cases, accelerates. The US Food and Drug Administration (FDA) has cleared a series of approvals in 2025 that not only respond to long-standing clinical needs but also redefine what’s possible across multiple therapeutic areas.